

Resource Summary Report

Generated by [dkNET](#) on Jul 30, 2026

FITC anti-human CD3

RRID:AB_314042

Type: Antibody

Proper Citation

BioLegend Cat# 300306, RRID:AB_314042

Antibody Information

URL: http://antibodyregistry.org/AB_314042

Proper Citation: BioLegend Cat# 300306, RRID:AB_314042

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: FITC anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone HIT3a

Antibody ID: AB_314042

Vendor: BioLegend

Catalog Number: 300306

Alternative Catalog Numbers: 300305

Record Creation Time: 20250820T001722+0000

Record Last Update: 20250820T075229+0000

Ratings and Alerts

No rating or validation information has been found for FITC anti-human CD3.

No alerts have been found for FITC anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Murdock BJ, et al. (2025) Early immune system changes in amyotrophic lateral sclerosis correlate with later disease progression. *Med (New York, N.Y.)*, 6(8), 100673.

Pham J, et al. (2025) Nanobioreactor detection of space-associated hematopoietic stem and progenitor cell aging. *Cell stem cell*, 32(9), 1403.

Di Meo F, et al. (2025) Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma. *Cancer cell*, 43(12), 2298.

Hu J, et al. (2025) CD169+ macrophages identify and eliminate tumor cells in colorectal cancer through CD169/CD43 interaction and FasL-driven apoptosis. *Cell reports*, 44(10), 116351.

Navarro P, et al. (2025) Multicenter study correlating molecular characteristics and clinical outcomes of cancer cases with patient-derived organoids. *Journal of experimental & clinical cancer research : CR*, 44(1), 182.

Wan X, et al. (2025) Therapeutic T cells with 3-in-1 strategy for the treatment of biliary tract cancer. *Cell reports. Medicine*, 102349.

Bie L, et al. (2025) Benmelstobart plus anlotinib and chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: A phase 2 study. *Cell reports. Medicine*, 6(6), 102145.

Shah Z, et al. (2024) Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer. *Cell stem cell*, 31(6), 803.

Wu N, et al. (2024) MerTK+ macrophages promote melanoma progression and immunotherapy resistance through AhR-ALKAL1 activation. *Science advances*, 10(40), eado8366.

Vyasamneni R, et al. (2023) A universal MHCII technology platform to characterize antigen-specific CD4+ T??cells. *Cell reports methods*, 3(1), 100388.

Crews LA, et al. (2023) Reversal of malignant ADAR1 splice isoform switching with Rebecsinib. *Cell stem cell*, 30(3), 250.

Morita R, et al. (2023) COVID-19 relapse associated with SARS-CoV-2 evasion from CD4+ T-cell recognition in an agammaglobulinemia patient. *iScience*, 26(5), 106685.

Wu X, et al. (2023) Multiomic landscape of immune pathogenesis in Kimura's disease. *iScience*, 26(4), 106559.

Liu X, et al. (2023) Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. *Cancer cell*, 41(2), 272.

Imbrechts M, et al. (2022) Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model. *iScience*, 25(8), 104705.

Sutton HJ, et al. (2021) Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans. *Cell reports*, 34(6), 108684.

Mondala PK, et al. (2021) Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. *Cell stem cell*, 28(4), 623.

Jiang Q, et al. (2021) Inflammation-driven deaminase deregulation fuels human pre-leukemia stem cell evolution. *Cell reports*, 34(4), 108670.

Zhou Y, et al. (2020) Single-Cell Multiomics Sequencing Reveals Prevalent Genomic Alterations in Tumor Stromal Cells of Human Colorectal Cancer. *Cancer cell*, 38(6), 818.

Ott PA, et al. (2020) A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. *Cell*, 183(2), 347.